Terms: = Liver cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Treatment
169 results:
1. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
[TBL] [Abstract] [Full Text] [Related]
2. How CLSPN could demystify its prognostic value and potential molecular mechanism for hepatocellular carcinoma: A crosstalk study.
Shi Y; Wang Y; Niu K; Zhang W; Lv Q; Zhang Y
Comput Biol Med; 2024 Apr; 172():108260. PubMed ID: 38492457
[TBL] [Abstract] [Full Text] [Related]
3. SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation.
Zhang S; Jia X; Dai H; Zhu X; Song W; Bian S; Wu H; Chen S; Tang Y; Chen J; Jin C; Zhou M; Xie H; Zheng S; Song P
Cancer Commun (Lond); 2024 Mar; 44(3):384-407. PubMed ID: 38407942
[TBL] [Abstract] [Full Text] [Related]
4. RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.
Guo Y; Chai B; Zhang H; Chai X; Chen Y; Xu J; Qin L; Chai Y
Biol Direct; 2024 Feb; 19(1):15. PubMed ID: 38388961
[TBL] [Abstract] [Full Text] [Related]
5. USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis.
Zhang N; Zhang H; Yang X; Xue Q; Wang Q; Chang R; Zhu L; Chen Z; Liu X
BMC Cancer; 2024 Feb; 24(1):237. PubMed ID: 38383348
[TBL] [Abstract] [Full Text] [Related]
6. Ubiquitination-specific protease 7 enhances stemness of hepatocellular carcinoma by stabilizing basic transcription factor 3.
Hu M; Dai C; Sun X; Chen Y; Xu N; Lin Z; Xu S; Cheng C; Tan Z; Bian S; Zheng W
Funct Integr Genomics; 2024 Feb; 24(1):28. PubMed ID: 38340226
[TBL] [Abstract] [Full Text] [Related]
7. HBV promotes its replication by up-regulating RAD51C gene expression.
Peng TW; Ma QF; Li J; Wang X; Zhang CH; Ma J; Li JY; Wang W; Zhu CL; Liu XH
Sci Rep; 2024 Jan; 14(1):2607. PubMed ID: 38297111
[TBL] [Abstract] [Full Text] [Related]
8. Downregulation of Roundabout guidance receptor 2 suppresses hepatocellular carcinoma progression by interacting with Y-box binding protein 1.
Liu T; Zhai C; Tian B; Li C; Han S; Wang S; Xuan M; Liu D; Zhao Y; Zhao H; Yu W; Wang J
Sci Rep; 2024 Jan; 14(1):2588. PubMed ID: 38297025
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study.
Hu Z; Hu Z; Zhan W; Wu W; Zhou Z; Chen M; Fu Y; Zhang Y
Int Immunopharmacol; 2024 Jan; 127():111413. PubMed ID: 38118318
[TBL] [Abstract] [Full Text] [Related]
10. RIT1 regulates mitosis and promotes proliferation by interacting with SMC3 and PDS5 in hepatocellular carcinoma.
Su Y; Lin H; Yu J; Mao L; Jin W; Liu T; Jiang S; Wu Y; Zhang S; Geng Q; Ge C; Zhao F; Chen T; Cui Y; Li J; Hou H; Zhou X; Li H
J Exp Clin Cancer Res; 2023 Nov; 42(1):326. PubMed ID: 38017479
[TBL] [Abstract] [Full Text] [Related]
11. Disparities in outcomes and access to therapy options in hepatocellular carcinoma.
Beltrán Ponce S; Gokun Y; Douglass F; Dawson L; Miller E; Thomas CR; Pitter K; Conteh L; Diaz DA
J Natl Cancer Inst; 2024 Feb; 116(2):264-274. PubMed ID: 37831897
[TBL] [Abstract] [Full Text] [Related]
12. Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation.
Xie L; Qiu S; Lu C; Gu C; Wang J; Lv J; Fang L; Chen Z; Li Y; Jiang T; Xia Y; Wang W; Li B; Xu Z
J Exp Clin Cancer Res; 2023 Oct; 42(1):258. PubMed ID: 37789385
[TBL] [Abstract] [Full Text] [Related]
13. The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis.
Liu M; Zhao T; Zhang Y; Zhang AM; Geng J; Xia X
Front Cell Infect Microbiol; 2023; 13():1226755. PubMed ID: 37771696
[TBL] [Abstract] [Full Text] [Related]
14. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
Lyu MA; Tang X; Khoury JD; Raso MG; Huang M; Zeng K; Nishimoto M; Ma H; Sadeghi T; Flowers CR; Parmar S
Front Immunol; 2023; 14():1217121. PubMed ID: 37736101
[TBL] [Abstract] [Full Text] [Related]
15. Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy.
Ma Z; Chen W; Liu Y; Yu L; Mao X; Guo X; Jiang F; Guo Q; Lin N; Zhang Y
Autophagy; 2024 Mar; 20(3):541-556. PubMed ID: 37733919
[TBL] [Abstract] [Full Text] [Related]
16. Constitutive photomorphogenic protein 1 ubiquitinates interleukin-1 receptor accessory protein in human liver cancer.
Cao K; Liu Z; Liu J; Hu Q; Shan W; Hu B; Shi H; Zhang B
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16247-16260. PubMed ID: 37700160
[TBL] [Abstract] [Full Text] [Related]
17. Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma.
Li Y; Wang C; Yin X; Jiang L; Li X; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14879-14888. PubMed ID: 37599316
[TBL] [Abstract] [Full Text] [Related]
18. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract] [Full Text] [Related]
19. Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure.
Murakami S; Uchida T; Imamura M; Suehiro Y; Namba M; Fujii Y; Uchikawa S; Teraoka Y; Fujino H; Ono A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Miki D; Hayes CN; Tsuge M; Ohira M; Ohdan H; Oka S
J Gastroenterol Hepatol; 2023 Sep; 38(9):1637-1646. PubMed ID: 37475200
[TBL] [Abstract] [Full Text] [Related]
20. Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Takada H; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Muraoka M; Suzuki Y; Sato M; Kobayashi S; Yoshida T; Takano S; Maekawa S; Enomoto N
Oncology; 2023; 101(10):655-663. PubMed ID: 37379802
[TBL] [Abstract] [Full Text] [Related]
[Next]
